Insight
Understanding incontinence: beyond leaks, a guide to a common condition
By Gloria Kolb, co-founder and CEO of Elitone
Incontinence — often whispered about or ignored due to embarrassment — is a prevalent and significant health concern affecting millions worldwide.
Defined as the involuntary loss of bladder or bowel control, it manifests in various forms, from occasional leaks to frequent urges that disrupt daily life. Despite its widespread impact, incontinence remains under-discussed and misunderstood, leading many affected individuals to suffer in silence.
By shedding light on this common condition, I want to empower individuals to seek help, improve their quality of life, and break the stigma surrounding incontinence. Whether you’re navigating occasional leaks or more persistent symptoms, knowledge and support are crucial steps toward managing and overcoming the challenges of incontinence effectively.
What is incontinence?
Incontinence encompasses a spectrum of conditions characterised by the involuntary loss of bladder or bowel control, affecting people of all ages and genders. The most common types include stress incontinence, which involves leakage during activities such as coughing, sneezing, or exercising due to weakened pelvic floor muscles.
Urge incontinence is marked by a sudden and intense urge to urinate, often leading to leakage before reaching a restroom. Overflow incontinence occurs when the bladder is overly full, but there is no signal to urinate, causing frequent dribbling or leakage.
For many individuals, incontinence represents more than just a physical inconvenience; it can profoundly impact daily routines, social interactions, and emotional wellbeing. The condition may stem from various factors, including age-related changes, childbirth, pelvic floor disorders, neurological conditions, or certain medications.
Understanding the type of incontinence one experiences is crucial for determining appropriate management strategies, which range from lifestyle modifications and pelvic floor exercises to medical interventions and, in severe cases, surgical procedures.
Causes and risk factors
Incontinence can arise from a combination of factors related to bladder function, pelvic floor muscle strength, and overall health.
Common causes include:
- Age: As people age, bladder muscles may weaken, leading to increased susceptibility to incontinence.
- Childbirth: The strain and trauma of pregnancy and childbirth can weaken pelvic floor muscles, contributing to urinary leakage.
- Menopause: Hormonal changes during menopause can lead to changes in muscle strength and wall lining, leading to an increased incidence of incontinence.
- Chronic conditions: Conditions such as diabetes, obesity, and neurological disorders can affect bladder control.
- Medications: Certain medications, including diuretics and sedatives, can contribute to bladder control problems.
- Smoking: Tobacco use is associated with a higher risk of bladder control issues.
Understanding these factors helps individuals and healthcare providers identify potential contributors to incontinence and tailor treatment plans accordingly. Addressing underlying causes through lifestyle modifications, pelvic floor exercises, and medical interventions can significantly improve bladder control and quality of life.
Symptoms and impact
Incontinence manifests in various ways that can significantly affect daily life. One of the most common symptoms is urinary leakage, which occurs during activities like coughing, sneezing, laughing, or physical exertion, known as stress incontinence.
Another key symptom is urgency, characterised by sudden and intense urges to urinate that often result in involuntary leakage before reaching a restroom, known as urge incontinence.
Individuals may also experience increased frequency of urination, waking up multiple times at night to urinate (nocturia), and continuous or frequent dribbling of urine due to an overfull bladder (overflow). These symptoms can lead to substantial disruptions, impacting social interactions, emotional wellbeing, and overall quality of life.
Many people with incontinence face embarrassment, anxiety, and limitations in daily activities due to concerns about leakage and the need for frequent access to restroom facilities. Early recognition of these symptoms and timely intervention are crucial to managing incontinence effectively and improving one’s ability to lead a fulfilling life.
Treatment options
Treating incontinence involves a range of approaches tailored to the type and severity of symptoms experienced. For stress incontinence, which is often caused by weakened pelvic floor muscles, pelvic floor exercises (Kegel exercises) are commonly recommended to strengthen these muscles and improve bladder control.
Lifestyle changes such as maintaining a healthy weight, avoiding caffeine and alcohol, and quitting smoking can also help alleviate symptoms.
External solutions, such as wearable devices that tone the pelvic floor and calm overactive bladder symptoms, offer innovative alternatives. These devices provide electrical stimulation to improve muscle function and bladder control. They can be used alongside other treatments to enhance effectiveness.
For more severe or persistent cases of incontinence, medical interventions may be necessary. These can include minimally invasive procedures, such as injections of bulking agents around the urethra to help close the bladder opening and prevent leakage.
Nerve stimulation techniques, like sacral neuromodulation, can also help regulate bladder function by sending electrical pulses to the nerves that control an overactive bladder.
Consulting with a healthcare provider can help determine the most appropriate treatment plan to enhance bladder control and restore quality of life, but typically start with the most conservative and least invasive (and costly) treatments.
Future directions and innovations
Looking ahead, ongoing research and innovation in the field of incontinence offer promising avenues for improving treatment outcomes and quality of life for affected individuals.
Advances in wearable technology continue to refine devices that provide biofeedback and electrical stimulation, enhancing their effectiveness in strengthening pelvic floor muscles and managing bladder function.
Additionally, there is growing interest in personalised medicine approaches tailored to individual genetic profiles and specific types of incontinence. This could lead to more targeted treatments that address underlying causes and optimise therapeutic outcomes.
Furthermore, collaborative efforts between healthcare providers, researchers, and technology developers are driving the development of novel therapies and interventions. From advanced surgical techniques to non-invasive treatment options, the future holds promise for more effective, minimally disruptive solutions for managing and potentially curing incontinence.
By staying informed about these advancements and engaging in discussions with healthcare providers, individuals can look forward to a future where managing incontinence is more accessible, effective, and empowering.
Gloria Kolb is the CEO and co-founder of Elitone, the first non-invasive, FDA-cleared, wearable treatment for women with urinary incontinence. Elitone’s accolades include winning Best New Product by My Face My Body, Sling Shot 2020, finalist in Women Startup Challenge, and many startup pitch competitions. As an inventor with 30+ patents, Gloria has been featured in Forbes as a Top Scientist Driving Innovation in Women’s Health. Her designs and problem-solving abilities have earned her recognition, such as Boston’s “40 Under 40” and MIT Review’s “World’s Top Innovators under 35.” She has engineering degrees from MIT and Stanford and an entrepreneurship MBA from Babson College.

Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
News
WHO hosts parliamentary dialogue on women’s health
The World Health Organization (WHO) welcomed a delegation of parliamentarians to its Geneva headquarters for a high-level dialogue on women’s health and sexual and reproductive health and rights.
The meeting on 20 January 2026 focused on women’s health, sexual and reproductive health and rights, noncommunicable diseases (long-term conditions such as cancer and diabetes) and global health cooperation.
The exchange was convened by the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, bringing together parliamentarians from Albania, Germany, Georgia, Mexico, Slovakia, South Africa, Sri Lanka, Sweden and Zimbabwe.
A central theme was the need to move beyond fragmented approaches to women’s health.
Dr Alia El-Yassir, WHO director for gender, equity and diversity, highlighted that outcomes are shaped by gender inequalities, social norms and structural barriers across the life course, requiring coordinated action across health systems.
Thirty years after the Beijing Declaration and Platform for Action, a landmark framework adopted in 1995 to advance gender equality and women’s rights, Dr Anna Coates, WHO gender equality technical lead, noted that progress on women’s health remains uneven.
She called for health systems that are more gender-responsive and able to address women’s health holistically across the life course.
Parliamentarians stressed that health is inseparable from wider social and economic policies, and called for stronger links between evidence, legislation and measurable impact at country level.
The meeting also focused on sexual and reproductive health and rights, where parliamentarians expressed interest in engaging on issues that directly affect their constituents.
Dr Pascale Allotey, director of WHO’s Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing, outlined WHO’s life-course approach to sexual and reproductive health and rights.
She highlighted how needs evolve from birth to older age and how these are shaped by social determinants, humanitarian crises and demographic trends.
Dr Allotey underscored the role of parliamentarians in advancing sexual and reproductive health and rights and the importance of continued engagement with WHO to support evidence-based policy-making.
The agenda highlighted cancer as a growing priority for women’s health and for health system sustainability. Dr Prebo Barango, lead for the Cervical Cancer Elimination Initiative, Dr Meghan Doherty, consultant for palliative care, and Santiago Milan, lead for the WHO Global Platform for Access to Childhood Cancer Medicine, presented WHO’s integrated approach to cancer control.
Palliative care is treatment and support that aims to improve quality of life for people with serious illness by managing pain and other symptoms.
The discussion underlined the need for sustained political commitment and domestic investment to address noncommunicable diseases.
Parliamentarians shared national experiences showing the social and economic impacts of cancer on families and caregivers, reinforcing the importance of improving health literacy, reducing stigma and delivering people-centred care.
The meeting also addressed the state of global multilateralism.
Dr Jeremy Farrar, assistant director-general for health promotion, disease prevention and care, outlined how WHO has restructured to enhance efficiency, impact and capacity to support countries.
He reaffirmed WHO’s commitment to more systematic engagement with parliaments, recognising their role in shaping health policy, legislation and budgets.
The exchange concluded with a call for continued collaboration, including through partnerships with the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, ahead of the UNITE Global Summit 2026 on 6–7 March in Manila, the Philippines.
Insight
FDA approves Agilent test for ovarian cancer
Agilent has FDA approval for a test to identify ovarian cancer patients who may be eligible for immunotherapy.
Agilent’s PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic to help identify patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours express PD-L1 and who may be eligible for treatment with KEYTRUDA, Merck’s anti-PD-1 therapy.
A companion diagnostic is a test used alongside a specific treatment to show whether a patient is suitable for that therapy. PD-L1 is a protein on some cancer cells that helps tumours evade the immune system.
These cancers affect the reproductive system and the lining of the abdominal cavity.
The test enables pathologists to assess PD-L1 expression at diagnosis to support treatment decisions in a disease where options remain limited for many.
This is the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA.
Nina Green, vice president and general manager of Agilent’s clinical diagnostics division, said: “Delivering effective precision oncology requires close collaboration between diagnostics and therapeutics, and this FDA approval reflects Agilent’s long-standing industry partnership in companion diagnostics.
“We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy.
“As the first immuno-oncology approval for this disease, this milestone underscores our commitment to advancing precision medicine and expanding access to innovative cancer treatments worldwide.”
PD-L1 expression with this test was evaluated in the KEYNOTE-B96 clinical trial supporting its use to identify patients who may benefit from KEYTRUDA.
In the US, ovarian cancer caused approximately 12,730 deaths in 2025 and the five-year survival rate was 51.6 per cent between 2015 and 2021.
In addition to these cancer types, the test is indicated in the US to help identify patients with non-small cell lung cancer, oesophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer and gastric or gastro-oesophageal junction adenocarcinoma who may benefit from treatment with KEYTRUDA.
The test was developed by Agilent with Merck as a companion diagnostic for KEYTRUDA.
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Pregnancy6 days agoFrance urges 29-year-olds to start families now






3 Comments